Veeda Clinical Research acquires European CRO, Heads to expand global reach & capabilities
Overview
Veeda Clinical Research a full-service contract research organization (CRO) has acquired Heads, a privately held European CRO, which specializes in conducting clinical trials in oncology.
About Heads
- Established in 2010, Heads has operational presence in 25 multiple strategically important locations across Europe, North America and Asia Pacific region.
- Through this acquisition, Veeda enters the league of global CROs with integrated capabilities to extend contract research services from discovery to clinical development extending to post commercial launch.
Acquisition Benefits: for Heads
- The acquisition provides Heads a strong operational platform and an opportunity to expand its expertise and capabilities to the Indian and South-East Asian markets.
- India's diverse demographic profile provides a unique opportunity to conduct clinical trials, especially in therapeutic areas including oncology, diabetes, hypertension, infectious diseases, and special diseases.
Acquisition Benefits: for Veeda
- With this acquisition, Veeda’s global pharmaceutical and biotech clients can now leverage the unique and unparalleled suite of early to late-phase CRO services across Europe, US, and Asia Pacific.
- Veeda’s ever-growing relationship with large biopharma companies and access to KOL’s across multiple countries will accelerate execution of global clinical trials in both the western and eastern populations.
- In recent years, Veeda has added expertise in the late stage clinical and global trials for large molecules.
- High quality and efficient clinical trial execution remains the top priority for the clients of the combined entity.
Words from CEO: Veeda Clinical Research
Dr. Mahesh Bhalgat, group- CEO, Veeda Clinical Research, said, “With the growing emphasis on global clinical trials, this acquisition now positions Veeda to offer access to a very diverse population for conducting large scale multi-geography trials efficiently. Both organizations are focused towards driving equitable access to trials and fostering the development of innovative treatments worldwide. The acquisition brings together a unique team of scientists and researchers, having deep therapeutic area expertise in the oncology research. This equips Veeda to build long and enduring site relationships across geographies.
"There is a very strong cultural fit between Heads and Veeda," said Dr. George Kouvatseas, partner, Heads. Both companies share a dedication to scientific leadership, expansion of highly specialized services to meet the emerging needs of our clients, an uncompromising focus on quality, and a belief that our strength is in our people and the way in which they work together.
Responsibilities Post Acquisition
- During the integration phase, Heads will continue to offer uninterrupted support to client programmes.
- The Veeda and Heads organization together are committed to nimble operations through a structured integration process without impact to ongoing client programmes.
